2023
DOI: 10.1016/s0302-2838(23)00573-0
|View full text |Cite
|
Sign up to set email alerts
|

An exploratory prospective clinical study on efficacy and safety of anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles